Procter & Gamble Health Ltd: Strong FY26 Performance and Dividend Payout

Procter & Gamble Health Ltd has posted robust financial results for the fiscal year ending March 31, 2026. The company reported revenue from operations of ₹1,407.97 crore and a Profit After Tax (PAT) of ₹326.91 crore. The Board has recommended a total dividend of ₹205 per share.

Reader Takeaway: Solid growth driven by trusted brands and innovation, but ongoing legal cases are a concern.

What just happened

Procter & Gamble Health Ltd announced its financial results for the fiscal year 2025-26. Key highlights include a revenue of ₹1,407.97 crore and a PAT of ₹326.91 crore, marking significant growth from the previous nine-month period. The company also declared a substantial total dividend of ₹205 per share, comprising an interim dividend of ₹160 and a final dividend of ₹45. An operating profit margin of 31.56% was reported.

Why this matters

The strong revenue and profit figures indicate healthy business momentum and effective strategy execution. The substantial dividend payout signals confidence in the company's financial health and its commitment to returning value to shareholders. The appointment of a new CFO is also a key leadership change.

The backstory

In the prior nine-month period (FY 2024-25), the company had reported revenue of ₹934.17 crore and PAT of ₹234.41 crore. The current fiscal year shows a significant uplift, attributed to a focused portfolio of trusted brands and successful product launches like Livogen Iron Gummies.

What changes now

Investors can expect continued focus on premiumization and innovation in the VMS segment. The dividend will be paid out to eligible shareholders. The company's financial strategy will be led by the new CFO, Mr. Shashank Srowthy.

Risks to watch

The company faces ongoing litigation with tax authorities and the National Pharmaceutical Pricing Authority (NPPA) concerning price fixation and overcharging claims. Raw material cost pressures due to inflation also remain a monitoring point.

Peer comparison

While specific peer data is not provided in the filing, P&G Health operates in the competitive VMS and pharmaceutical segments. Its focus on established brands and product innovation is a key differentiator in this market.

Context metrics (time-bound)

Revenue from operations for FY 2025-26 stood at ₹1,407.97 crore. Profit after taxation was ₹326.91 crore. The operating profit margin was 31.56%. The inventory turnover ratio improved to 11.45 from 8.55 in the previous year.

What to track next

Investors should closely monitor the outcomes of the ongoing legal disputes with tax authorities and the NPPA. Management's ability to manage inflationary pressures on raw material costs will also be crucial. The performance of new product launches, such as Livogen Iron Gummies, will be key indicators of future growth.